Table 2 Baseline characteristics of the patients included in systematic review

Singh[2016] [22]

CD/UC

52

14.9(7–17)

32.5 (17.5–45)

30 (IQR 10–55)

300 mg(n = 39); 6 mg/kg(n = 11);

5 mg/kg(n = 2)

47/52

IFX^b

ADA^b

CZP^b

AZA/6-MP/MTX:15/52

CS:29/52

NR

Conrad[2016] [23]

CD/UC/IBD-U

21

13–18 (n = 15);

19–21 (n = 6)

25.0 (IQR 17.5–38.1)

30.0 (IQR 20.0–35.0)

300 mg

21/21

IFX:20/21

ADA:13/21

CZP:2/21

GLM:1/21

AZA/6-MP:1/21

MTX:8/21

CS:15/21

B1 9/16

B2 3/16

B3 2/16

B2&B3 2/16

P 8/16

Ledder[2017] [24]

CD/UC/IBD-U

64

10.7 ± 3.6

37.5 (IQR 24–61)

45 (IQR 30–65)

300 mg(n = 52);

150-250 mg(3.6–10.3 mg/kg)(n = 12)

64/64

Anti-TNF-α^c

TAC:4/64

THA:1/64

AZA/6-MP/MTX:21/64

CS:41/64

B1 17/23

B2 5/23

B3 1/23

P 4/23

G 15/23

Schneider[2018] [25]

CD/UC/IBD-U

12

15(8–17)

Median:47.5

Median:70

6 mg/kg(Max 300 mg)

12/12

IFX:12/12

ADA:11/12

GLM:1/12

CS:8/11

AZA:3/11

5-ASA:2/11

NR

Olbjørn[2020] [26]

CD/UC

8

17(14–17.5)

68.75(IQR 65–76.25)

67.5(IQR 55.63–73.75)

300 mg

8/8

IFX:8/8

CS:8/8

AZA:3/8

MTX:3/8

5-ASA:5/8

IFX:8/8

B1 2/4

B3 2/4

P 1/4

Jossen[2020] [27]

CD/UC

68

16.4(IQR 13.3–18.2)

Anti-TNF naïve:26.2 (IQR 19.4–35.6)

Anti-TNF exposed: 35 (IQR 25–57.5)

pMS: Anti-TNF naïve: 3.5 (2–5)

pMS: Anti-TNF exposed: 6 (3–6.5)

 ≥ 30 kg:300 mg

19-29 kg:6-10 mg/kg

36/68

NR

CS:44/68

B1 29/33

B2 3/33

B3 1/33

P 10/33

Dolinger[2021] [28]

CD/UC/IBD-U

13

15.9 (IQR 13.5–16.9)

58.75 (IQR 31.25–58.75)

pMS:4 (IQR 0–7)

300 mg

13/13

Anti-TNF-α^c

NR

B1 6/7

B2 1/7

Fabiszewska[2021] [29]

CD/UC

16

6.5(2.2–16.5)

34.4 ± 1.9

26 ± 6

150 mg or 300 mg depending on patient’s weight

15/16

IFX:15/16

ADA:9/16

Other biologics:4/16

CS:16/16

BUD:8/16

5-ASA:15/16

AZA:14/16

CsA:10/16

During induction phase:

AZA:5/16

MTX:4/16

CS:8/16

During maintenance phase:

AZA:4/14

MTX:4/14

CS:6/14

NR

Garcia-Romero [2021] [30]

CD/UC

42

12.6(IQR 8.9–14.0)

36 (IQR 24–60)

47 (IQR 25–65)

 < 40 kg: 6 mg/kg (n = 20)

300 mg (n = 22)

42/42

IFX:40/42

ADA:26/42

ADA + IFX:24/42

Oral CS:39/42

IV CS:28/42

AZA:40/42

6-MP:4/42

MTX:12/42

CsA:5/42

5-ASA:34/42

CS:22/42

AZA:19/42

6-MP:1/42

MTX:6/42

5-ASA:22/42

TAC:2/22

B1 13/14

B2 0/14

B3 1/14

G 5/14

Hajjat[2021] [31]

CD/UC/IBD-U

159

14.5 ± 2.4

27.5 (IQR 15–40)

50 (IQR 35–65)

At VED start: 6.0 ± 1.8 mg/kg;

At VED end: 5.2 ± 1.9 mg/kg

136/159

IFX:132/159

ADA:66/159

GLM:2/159

CZP:14/159

UST:5/159

CS:105/159

AZA:16/159

6-MP:48/159

MTX:82/159

5-ASA:78/159

SUL:19/159

RT:72/159

CS:101/159

AZA: 9/159

MTX: 46/159

B1 44/78

B2 17/78

B3 6/78

B2&B3 11/78